Eli Lilly’s Point Biopharma acquisition doesn’t change our optimism on the diabetes-and-obesity drug giant heading into the new year.
Sumber: www.cnbc.com
Eli Lilly’s Point Biopharma acquisition doesn’t change our optimism on the diabetes-and-obesity drug giant heading into the new year.
Sumber: www.cnbc.com